Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615179 · ClinicalTrials.gov registry record
Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
A clinical trial, sponsored by Sanofi.
- Completed
- Registry status
- 4,545
- Enrollment target
NCT07615179 is a clinical trial that has completed, run by Sanofi. The registered enrollment target is 4,545 participants.
The verdict
NCT07615179 has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- 4,545 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.
Interventions
- DRUG Alirocumab
- DRUG Comparator: No PCSK9i Therapy (either mAb or siRNA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,545 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2026-05-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07615179
The ClinicalTrials.gov registry entry for NCT07615179 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,545 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alirocumab is the first listed.
NCT07615179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07615179 about?
NCT07615179 is a clinical study titled "Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)". The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PC...
What is the current status of trial NCT07615179?
This trial is currently completed. The enrollment target is 4,545 participants. The study started on 2025-02-17. Estimated completion is 2026-05-30.
What interventions are being tested in trial NCT07615179?
The interventions under investigation include: Alirocumab (DRUG), Comparator: No PCSK9i Therapy (either mAb or siRNA) (DRUG).
Who is sponsoring clinical trial NCT07615179?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.